Evaluation of neuroprotective and immunomodulatory properties of mesenchymal stem cells in an ex vivo retinal explant model
Background Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation re...
Saved in:
| Published in | Journal of neuroinflammation Vol. 19; no. 1; pp. 63 - 17 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
02.03.2022
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1742-2094 1742-2094 |
| DOI | 10.1186/s12974-022-02418-w |
Cover
| Abstract | Background
Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model.
Methods
Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both ‘M1’ or
classically activated
state inflammatory cytokines (TNFα, IL1β, and IL6), and ‘M2’ or
alternatively activated
state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6).
Results
The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype.
Conclusion
Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling. |
|---|---|
| AbstractList | Background
Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model.
Methods
Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both ‘M1’ or
classically activated
state inflammatory cytokines (TNFα, IL1β, and IL6), and ‘M2’ or
alternatively activated
state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6).
Results
The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype.
Conclusion
Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling. Background Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model. Methods Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNF[alpha], IL1[beta], and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6). Results The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype. Conclusion Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling. Keywords: Glaucoma, Neuroprotection, Immunomodulation, Cellular therapy, Mesenchymal stem cell, Microglia, Retinal ganglion cell Background: Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model. Methods: Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNFα, IL1β, and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6). Results: The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype. Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model. Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNFα, IL1β, and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6). The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype. Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling. Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model. Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNF[alpha], IL1[beta], and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6). The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype. Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling. Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model.BACKGROUNDGlaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model.Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNFα, IL1β, and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6).METHODSLabeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNFα, IL1β, and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6).The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype.RESULTSThe number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype.Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling.CONCLUSIONUsing an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling. Abstract Background Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model. Methods Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both ‘M1’ or classically activated state inflammatory cytokines (TNFα, IL1β, and IL6), and ‘M2’ or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6). Results The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype. Conclusion Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling. |
| ArticleNumber | 63 |
| Audience | Academic |
| Author | Mélik Parsadaniantz, Stéphane Reboussin, Élodie Riancho, Luisa Réaux-Le Goazigo, Annabelle Brignole-Baudouin, Françoise Sahel, José-Alain Buffault, Juliette Olmiere, Céline Baudouin, Christophe |
| Author_xml | – sequence: 1 givenname: Élodie orcidid: 0000-0002-9264-1133 surname: Reboussin fullname: Reboussin, Élodie organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT – sequence: 2 givenname: Juliette orcidid: 0000-0002-4599-9749 surname: Buffault fullname: Buffault, Juliette email: jbuffault@15-20.fr organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT, Service 3, CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423 – sequence: 3 givenname: Françoise orcidid: 0000-0002-2006-5384 surname: Brignole-Baudouin fullname: Brignole-Baudouin, Françoise organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT, Laboratoire, CHNO des Quinze-Vingts – sequence: 4 givenname: Annabelle orcidid: 0000-0003-3855-9523 surname: Réaux-Le Goazigo fullname: Réaux-Le Goazigo, Annabelle organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT – sequence: 5 givenname: Luisa orcidid: 0000-0003-0972-2117 surname: Riancho fullname: Riancho, Luisa organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT – sequence: 6 givenname: Céline orcidid: 0000-0001-7551-1129 surname: Olmiere fullname: Olmiere, Céline organization: Laboratoires THEA – sequence: 7 givenname: José-Alain orcidid: 0000-0002-4831-1153 surname: Sahel fullname: Sahel, José-Alain organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT, Service 3, CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, Department of Ophthalmology, The University of Pittsburgh School of Medicine – sequence: 8 givenname: Stéphane orcidid: 0000-0003-2029-9591 surname: Mélik Parsadaniantz fullname: Mélik Parsadaniantz, Stéphane organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT – sequence: 9 givenname: Christophe orcidid: 0000-0003-1743-6698 surname: Baudouin fullname: Baudouin, Christophe organization: Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU FOReSIGHT, Service 3, CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423 |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35236378$$D View this record in MEDLINE/PubMed https://hal.sorbonne-universite.fr/hal-03598635$$DView record in HAL |
| BookMark | eNqNks1q3DAUhU1JaX7aF-iiGLpJF04t2ZalTWEIaRMY6KZdC1m-nlGQJVeSPRn68tWMpyETSijG2Fx950hX554nJ8YaSJL3KL9CiJLPHmFWl1mOcXxLRLPNq-QM1SXOcM7Kkyf_p8m59_d5XuCK4DfJaVHhghQ1PUt-30xCjyIoa1LbpQZGZwdnA8igJkiFaVPV96OxvW1HLYJ12zSuD-CCAr-T9ODByPW2Fzr1AfpUgtY-VSaKU3hIJzXZ1EFQJgLwMGhhQhrdQL9NXndCe3h3-F4kP7_e_Li-zZbfv91dL5aZJKgIWdtIUtCyhQaVVFKKcY4bWktU5Z2glSQtIqSpWAeyxlg0rKRFhytaCEqarkPFRXI3-7ZW3PPBqV64LbdC8X3BuhUXsR2pgTOoqagpblBFyy7HooIWKEhWA4iKNNGrmL1GM4jtRmj9aIhyvouFz7HwGAvfx8I3UfVlVg1j00MrwQQn9NFRjleMWvOVnTilDBNWR4NPs8H6mex2seS7Wl5UjJKimnbtXh42c_bXCD7wXvldKMKAHT3HEStrhkoS0Y8zuhKxeWU6G3eXO5wvCGMlQxhVkbr6BxWfFnol40x2KtaPBB-etvt44L9jFwE6A9JZ7x10XKqwH8LorPTLV4mfSf_r_g-p-QibFTh-b0cXB9K_pPoDThIOlA |
| CitedBy_id | crossref_primary_10_3389_fcell_2022_1068213 crossref_primary_10_1186_s40001_024_01987_1 crossref_primary_10_3390_biomedicines11102656 crossref_primary_10_1186_s40478_024_01859_z crossref_primary_10_1186_s10020_024_01058_5 crossref_primary_10_1007_s10753_023_01880_9 crossref_primary_10_1096_fj_202202056RR crossref_primary_10_3389_fcell_2023_1081898 crossref_primary_10_1089_dna_2024_0254 crossref_primary_10_1186_s40478_024_01753_8 crossref_primary_10_3390_ph16091193 crossref_primary_10_1007_s12015_023_10607_0 crossref_primary_10_1097_ICU_0000000000001016 crossref_primary_10_1186_s10020_025_01120_w crossref_primary_10_1016_j_jneumeth_2024_110181 crossref_primary_10_1016_j_yexcr_2024_114220 crossref_primary_10_1080_02713683_2023_2253378 |
| Cites_doi | 10.1167/iovs.18-25156 10.1002/stem.2095 10.1159/000497296 10.4103/1673-5374.245465 10.3389/fneur.2021.624983 10.3390/ijms19072016 10.1038/s41598-020-72875-x 10.3390/ijms21239330 10.1016/j.jcyt.2015.10.008 10.1167/iovs.10-6873 10.1167/iovs.07-1601 10.1186/1742-2094-11-98 10.3390/cells10040730 10.1016/j.brainres.2019.146422 10.1182/blood.V99.10.3838 10.3791/2241 10.1167/iovs.09-4509 10.1016/j.it.2004.09.015 10.1007/s00018-013-1290-8 10.1007/s12015-016-9688-y 10.1007/5584_2018_219 10.1016/j.ejphar.2016.03.064 10.1186/s12865-021-00443-7 10.4103/2008-322X.200164 10.1093/brain/awt292 10.1177/1759091415598292 10.3389/fnana.2017.00077 10.4274/tjo.89972 10.1097/ICB.0000000000000327 10.1186/s12974-021-02248-2 10.1016/j.exer.2019.107722 10.1016/j.jcyt.2014.12.005 10.1038/s41419-020-02955-3 10.1007/s12035-014-9070-5 10.1007/s10633-021-09817-z 10.1089/scd.2016.0349 10.1523/JNEUROSCI.14-07-04368.1994 10.1111/cei.12929 10.1186/s13287-015-0168-0 10.3390/cells10030588 10.4252/wjsc.v13.i6.632 10.1186/s12967-014-0260-8 10.3390/ijms22020763 10.1038/aps.2012.178 10.1016/j.preteyeres.2020.100916 10.1186/s13287-020-02122-7 10.1186/s12974-021-02263-3 10.3390/cells9030535 10.1111/ceo.13434 10.1056/NEJMoa1609583 10.3390/ijms222011077 10.1016/j.expneurol.2012.03.021 10.1016/j.exer.2016.07.010 10.1016/j.molmed.2015.02.008 10.1177/0271678X18776802 10.1016/bs.pbr.2020.05.026 10.1002/sctm.16-0428 10.1002/cne.23521 10.1016/j.ajo.2017.03.030 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES 5PM ADTOC UNPAY DOA |
| DOI | 10.1186/s12974-022-02418-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1742-2094 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_9e78a782b1584f02a5ede8ec97eea56b 10.1186/s12974-022-02418-w PMC8892697 oai_HAL_hal_03598635v1 A699491215 35236378 10_1186_s12974_022_02418_w |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM PMFND 7X8 1XC VOOES 5PM 2VQ 4.4 ADTOC AHSBF EJD H13 IPNFZ RIG UNPAY |
| ID | FETCH-LOGICAL-c613t-dbc6384deb148c882202b87c150fa85c6d166b59fec722ab9483f2583a86bff13 |
| IEDL.DBID | M48 |
| ISSN | 1742-2094 |
| IngestDate | Wed Aug 27 01:16:47 EDT 2025 Sun Sep 07 10:47:53 EDT 2025 Tue Sep 30 16:35:03 EDT 2025 Fri Sep 12 12:46:33 EDT 2025 Fri Sep 05 05:14:57 EDT 2025 Tue Jun 17 22:13:59 EDT 2025 Tue Jun 10 21:09:04 EDT 2025 Thu Apr 03 07:09:33 EDT 2025 Thu Apr 24 22:53:42 EDT 2025 Wed Oct 01 03:33:21 EDT 2025 Sat Sep 06 07:29:55 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Glaucoma Mesenchymal stem cell Neuroprotection Immunomodulation Cellular therapy Microglia Retinal ganglion cell |
| Language | English |
| License | 2022. The Author(s). Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c613t-dbc6384deb148c882202b87c150fa85c6d166b59fec722ab9483f2583a86bff13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-2029-9591 0000-0002-9264-1133 0000-0003-0972-2117 0000-0001-7551-1129 0000-0003-3855-9523 0000-0002-4831-1153 0000-0002-2006-5384 0000-0002-4599-9749 0000-0003-1743-6698 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12974-022-02418-w |
| PMID | 35236378 |
| PQID | 2635479146 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9e78a782b1584f02a5ede8ec97eea56b unpaywall_primary_10_1186_s12974_022_02418_w pubmedcentral_primary_oai_pubmedcentral_nih_gov_8892697 hal_primary_oai_HAL_hal_03598635v1 proquest_miscellaneous_2635479146 gale_infotracmisc_A699491215 gale_infotracacademiconefile_A699491215 pubmed_primary_35236378 crossref_citationtrail_10_1186_s12974_022_02418_w crossref_primary_10_1186_s12974_022_02418_w springer_journals_10_1186_s12974_022_02418_w |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-02 |
| PublicationDateYYYYMMDD | 2022-03-02 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of neuroinflammation |
| PublicationTitleAbbrev | J Neuroinflammation |
| PublicationTitleAlternate | J Neuroinflammation |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | JD Cherry (2418_CR14) 2014; 11 F Lazzara (2418_CR13) 2021; 18 MY García-Bermúdez (2418_CR12) 2021; 12 G Mannino (2418_CR24) 2021; 13 Z-Q Hua (2418_CR40) 2020; 257 F Carty (2418_CR26) 2017; 188 CR Harrell (2418_CR5) 2019; 2019 A Adornetto (2418_CR23) 2019; 14 TV Johnson (2418_CR38) 2008; 49 HA Quigley (2418_CR29) 1995; 36 M Berkelaar (2418_CR28) 1994; 14 TV Johnson (2418_CR7) 2010; 51 SD Nicoară (2418_CR25) 2021; 22 V Holan (2418_CR56) 2016; 12 Y Wang (2418_CR41) 2020; 11 K Allison (2418_CR1) 2020; 12 V Alarautalahti (2418_CR31) 2019; 60 M Di Nicola (2418_CR55) 2002; 99 Y Liu (2418_CR20) 2019; 1724 V Miceli (2418_CR60) 2021; 22 J Martins (2418_CR37) 2015 ND Bull (2418_CR36) 2012; 236 A Mantovani (2418_CR18) 2004; 25 AR Rodriguez (2418_CR34) 2014; 522 C Christakopoulos (2418_CR39) 2019; 186 R Russo (2418_CR11) 2016; 787 B Mathew (2418_CR63) 2021; 10 A Tuekprakhon (2418_CR50) 2021; 12 TV Johnson (2418_CR33) 2014; 137 AE Kuriyan (2418_CR47) 2017; 376 Y Hou (2418_CR22) 2021; 18 A Tassoni (2418_CR52) 2015; 33 MM Magharious (2418_CR27) 2011 C Roubeix (2418_CR8) 2015; 6 X Pereiro (2418_CR35) 2020; 21 CR Harrell (2418_CR61) 2018; 1089 JY Kim (2418_CR48) 2017; 11 T Zhou (2418_CR17) 2017; 11 ND Bull (2418_CR30) 2011; 52 S MélikParsadaniantz (2418_CR9) 2020; 9 AE Kuriyan (2418_CR46) 2017; 177 A Murali (2418_CR42) 2019; 47 VBR Konala (2418_CR53) 2016; 18 GD Kusuma (2418_CR58) 2017; 26 CAP Vilela (2418_CR45) 2021 A Öner (2418_CR6) 2018; 48 KN Mutoji (2418_CR19) 2021; 22 M Madrigal (2418_CR59) 2014; 12 CL Rettinger (2418_CR43) 2018; 206 L Satarian (2418_CR49) 2017; 12 FG Teixeira (2418_CR54) 2013; 70 Y Tang (2418_CR15) 2016; 53 Y Huang (2418_CR16) 2013; 34 V Holan (2418_CR2) 2021; 10 KA Jha (2418_CR21) 2018; 19 E Emre (2418_CR4) 2015; 17 U Pattamatta (2418_CR32) 2016; 151 HC Ray (2418_CR51) 2020; 10 B Mead (2418_CR62) 2017; 6 CJ Cunningham (2418_CR57) 2018; 38 Y Hu (2418_CR3) 2013; 8 C Baudouin (2418_CR10) 2020; 83 L Turner (2418_CR44) 2015; 21 |
| References_xml | – volume: 60 start-page: 1914 year: 2019 ident: 2418_CR31 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.18-25156 – volume: 33 start-page: 3006 year: 2015 ident: 2418_CR52 publication-title: Stem Cells doi: 10.1002/stem.2095 – volume: 206 start-page: 119 year: 2018 ident: 2418_CR43 publication-title: Cells Tissues Organs doi: 10.1159/000497296 – volume: 14 start-page: 391 year: 2019 ident: 2418_CR23 publication-title: Neural Regen Res doi: 10.4103/1673-5374.245465 – volume: 12 start-page: 624983 year: 2021 ident: 2418_CR12 publication-title: Front Neurol doi: 10.3389/fneur.2021.624983 – volume: 19 start-page: E2016 year: 2018 ident: 2418_CR21 publication-title: Int J Mol Sci doi: 10.3390/ijms19072016 – volume: 10 start-page: 15808 year: 2020 ident: 2418_CR51 publication-title: Sci Rep doi: 10.1038/s41598-020-72875-x – volume: 21 start-page: 9330 year: 2020 ident: 2418_CR35 publication-title: Int J Mol Sci doi: 10.3390/ijms21239330 – volume: 18 start-page: 13 year: 2016 ident: 2418_CR53 publication-title: Cytotherapy doi: 10.1016/j.jcyt.2015.10.008 – volume: 52 start-page: 3309 year: 2011 ident: 2418_CR30 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6873 – volume: 49 start-page: 3503 year: 2008 ident: 2418_CR38 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.07-1601 – volume: 11 start-page: 98 year: 2014 ident: 2418_CR14 publication-title: J Neuroinflamm doi: 10.1186/1742-2094-11-98 – volume: 10 start-page: 730 year: 2021 ident: 2418_CR63 publication-title: Cells doi: 10.3390/cells10040730 – volume: 1724 start-page: 146422 year: 2019 ident: 2418_CR20 publication-title: Brain Res doi: 10.1016/j.brainres.2019.146422 – volume: 99 start-page: 3838 year: 2002 ident: 2418_CR55 publication-title: Blood doi: 10.1182/blood.V99.10.3838 – year: 2011 ident: 2418_CR27 publication-title: J Vis Exp doi: 10.3791/2241 – volume: 51 start-page: 2051 year: 2010 ident: 2418_CR7 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.09-4509 – volume: 25 start-page: 677 year: 2004 ident: 2418_CR18 publication-title: Trends Immunol doi: 10.1016/j.it.2004.09.015 – volume: 70 start-page: 3871 year: 2013 ident: 2418_CR54 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-013-1290-8 – volume: 12 start-page: 654 year: 2016 ident: 2418_CR56 publication-title: Stem Cell Rev Rep doi: 10.1007/s12015-016-9688-y – volume: 1089 start-page: 47 year: 2018 ident: 2418_CR61 publication-title: Adv Exp Med Biol doi: 10.1007/5584_2018_219 – volume: 787 start-page: 134 year: 2016 ident: 2418_CR11 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2016.03.064 – volume: 22 start-page: 52 year: 2021 ident: 2418_CR19 publication-title: BMC Immunol doi: 10.1186/s12865-021-00443-7 – volume: 12 start-page: 58 year: 2017 ident: 2418_CR49 publication-title: J Ophthalmic Vis Res doi: 10.4103/2008-322X.200164 – volume: 137 start-page: 503 year: 2014 ident: 2418_CR33 publication-title: Brain doi: 10.1093/brain/awt292 – year: 2015 ident: 2418_CR37 publication-title: ASN Neuro doi: 10.1177/1759091415598292 – volume: 11 start-page: 77 year: 2017 ident: 2418_CR17 publication-title: Front Neuroanat doi: 10.3389/fnana.2017.00077 – volume: 48 start-page: 33 year: 2018 ident: 2418_CR6 publication-title: Turk J Ophthalmol doi: 10.4274/tjo.89972 – volume: 11 start-page: 227 year: 2017 ident: 2418_CR48 publication-title: Retin Cases Brief Rep doi: 10.1097/ICB.0000000000000327 – volume: 18 start-page: 216 year: 2021 ident: 2418_CR22 publication-title: J Neuroinflamm doi: 10.1186/s12974-021-02248-2 – volume: 186 start-page: 107722 year: 2019 ident: 2418_CR39 publication-title: Exp Eye Res doi: 10.1016/j.exer.2019.107722 – volume: 17 start-page: 543 year: 2015 ident: 2418_CR4 publication-title: Cytotherapy doi: 10.1016/j.jcyt.2014.12.005 – volume: 11 start-page: 793 year: 2020 ident: 2418_CR41 publication-title: Cell Death Dis doi: 10.1038/s41419-020-02955-3 – volume: 53 start-page: 1181 year: 2016 ident: 2418_CR15 publication-title: Mol Neurobiol doi: 10.1007/s12035-014-9070-5 – year: 2021 ident: 2418_CR45 publication-title: Doc Ophthalmol doi: 10.1007/s10633-021-09817-z – volume: 26 start-page: 617 year: 2017 ident: 2418_CR58 publication-title: Stem Cells Dev doi: 10.1089/scd.2016.0349 – volume: 14 start-page: 4368 year: 1994 ident: 2418_CR28 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.14-07-04368.1994 – volume: 188 start-page: 1 year: 2017 ident: 2418_CR26 publication-title: Clin Exp Immunol doi: 10.1111/cei.12929 – volume: 6 start-page: 177 year: 2015 ident: 2418_CR8 publication-title: Stem Cell Res Ther doi: 10.1186/s13287-015-0168-0 – volume: 10 start-page: 588 year: 2021 ident: 2418_CR2 publication-title: Cells doi: 10.3390/cells10030588 – volume: 13 start-page: 632 year: 2021 ident: 2418_CR24 publication-title: World J Stem Cells doi: 10.4252/wjsc.v13.i6.632 – volume: 12 start-page: 260 year: 2014 ident: 2418_CR59 publication-title: J Transl Med doi: 10.1186/s12967-014-0260-8 – volume: 22 start-page: E763 year: 2021 ident: 2418_CR60 publication-title: Int J Mol Sci doi: 10.3390/ijms22020763 – volume: 34 start-page: 6 year: 2013 ident: 2418_CR16 publication-title: Acta Pharmacol Sin doi: 10.1038/aps.2012.178 – volume: 2019 start-page: 7869130 year: 2019 ident: 2418_CR5 publication-title: Stem Cells Int – volume: 83 start-page: 100916 year: 2020 ident: 2418_CR10 publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2020.100916 – volume: 12 start-page: 52 year: 2021 ident: 2418_CR50 publication-title: Stem Cell Res Ther doi: 10.1186/s13287-020-02122-7 – volume: 8 start-page: 1467 year: 2013 ident: 2418_CR3 publication-title: Clin Interv Aging – volume: 18 start-page: 206 year: 2021 ident: 2418_CR13 publication-title: J Neuroinflamm doi: 10.1186/s12974-021-02263-3 – volume: 9 start-page: 535 year: 2020 ident: 2418_CR9 publication-title: Cells doi: 10.3390/cells9030535 – volume: 36 start-page: 774 year: 1995 ident: 2418_CR29 publication-title: Invest Ophthalmol Vis Sci – volume: 47 start-page: 274 year: 2019 ident: 2418_CR42 publication-title: Clin Exp Ophthalmol doi: 10.1111/ceo.13434 – volume: 376 start-page: 1047 year: 2017 ident: 2418_CR47 publication-title: N Engl J Med doi: 10.1056/NEJMoa1609583 – volume: 12 start-page: e11686 year: 2020 ident: 2418_CR1 publication-title: Cureus – volume: 22 start-page: 11077 year: 2021 ident: 2418_CR25 publication-title: Int J Mol Sci doi: 10.3390/ijms222011077 – volume: 236 start-page: 34 year: 2012 ident: 2418_CR36 publication-title: Exp Neurol doi: 10.1016/j.expneurol.2012.03.021 – volume: 151 start-page: 38 year: 2016 ident: 2418_CR32 publication-title: Exp Eye Res doi: 10.1016/j.exer.2016.07.010 – volume: 21 start-page: 271 year: 2015 ident: 2418_CR44 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2015.02.008 – volume: 38 start-page: 1276 year: 2018 ident: 2418_CR57 publication-title: J Cereb Blood Flow Metab doi: 10.1177/0271678X18776802 – volume: 257 start-page: 99 year: 2020 ident: 2418_CR40 publication-title: Prog Brain Res doi: 10.1016/bs.pbr.2020.05.026 – volume: 6 start-page: 1273 year: 2017 ident: 2418_CR62 publication-title: Stem Cells Transl Med doi: 10.1002/sctm.16-0428 – volume: 522 start-page: 1411 year: 2014 ident: 2418_CR34 publication-title: J Comp Neurol doi: 10.1002/cne.23521 – volume: 177 start-page: xix year: 2017 ident: 2418_CR46 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2017.03.030 |
| SSID | ssj0032562 |
| Score | 2.4537396 |
| Snippet | Background
Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and... Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually... Background Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and... Background: Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and... Abstract Background Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field... |
| SourceID | doaj unpaywall pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 63 |
| SubjectTerms | Animals Biomedical and Life Sciences Biomedicine Care and treatment Cellular therapy Disease Models, Animal Glaucoma Immunity Immunology Immunomodulation Life Sciences Mesenchymal stem cell Mesenchymal Stem Cells - metabolism Microglia Neurobiology Neurology Neuroprotection Neuroprotection - physiology Neuroprotective agents Neurosciences Rats Retina - metabolism Retinal Ganglion Cells - metabolism Testing |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagBx4HxLMECjIIiQONunEcP44LarVClBOVerMcx9GutJus9tlV_3xnnGzUqFLhwCGXxE6czOObJDPfEPIlK5BVhPm44FLEXFsfW65FLL1I2cBbqyQWCp__FqML_vMyu7zV6gtzwhp64ObBnWgvlQUYyxOAynLAbOYLr7zT0nubiRy9L8DY_mWq8cEpADnbl8gocbIEVJM8xsx1wKRExdseDAW2_s4nPxxjSuTdePNu2mT37_Qpebyu5na3tdPpLXg6e06etXElHTb384I88NVL8ui8_XP-ilyfdrTetC5poLFsORrA31FbFXSCpSL1rC6wo1e92NE5fqhfIOMqTplhnZIb72ZwGWR_pvjNf0knFUym_opuJpuaYk0krsNfzacgMxoa7bwmF2enf36M4rbxQuwA3VdxkTswS16AH-fKQQzOBixX0kHwWFqVOVEkQuSZLr2TjNlcc5WWLFOpVSIvyyR9Qw6quvJvCdXIDsOV5U7CJlieKTcoweq5V8IVIiLJXg7Gtazk2BxjasLbiRKmkZ0B2ZkgO7ONyLduzrzh5Lh39HcUbzcS-bTDDtAy02qZ-ZuWReQrKodBq4flOdsWL8BNIn-WGQqtuUamjogc9UaCtbre4c-gXr3FjIa_DO4LZIoQ_22SiHzaa5_B-ZgHV_l6vTRIHcSlBniLyGGjjd25IJRORSpVRGRPT3sX6x-pJuPAKK6UZkLLiBzvNdq0rmx575M97rT-HwTx7n8I4j15woIZY_bBETlYLdb-A4SFq_xj8AA3f0depQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLbYkIA9IO4EBjIIiQcWrXEcXx5LtalCjCcm7c1yHEet1CZVr6v25znHTaNFQxM85CXxSdyc29f4nM-EfMkKZBVhPi64FDHX1seWaxFLL1LW89YqiY3CF7_E8JL_uMquGpoc7IW5vX6fKHG6gHwkeYw155BNEhVvDsjDDAIvlu8NxGAfdVNI3WzfFPNXuU7iCfz8bRQ-GGER5F2EebdQsl0tPSKPV9XMbjd2MrmVkM6fkacNkqT9neqfkwe-ekEeXTRr5S_JzVlL5E3rkgbiyoaVASIctVVBx9gcUk_rAvfwqudbOsNP83PkWEWRKXYmudF2Co9BvmeKX_kXdFyBMPXXdD1e1xS7IHEe_no2AS3RsLXOK3J5fvZ7MIybrRZiB_l8GRe5A0fkBURurhygbtZjuZIO4GJpVeZEkQiRZ7r0TjJmc81VWrJMpVaJvCyT9DU5rOrKvyVUIx8MV5Y7CYdgeaZcrwQ_514JV4iIJHs9GNfwkON2GBMT_o8oYXa6M6A7E3RnNhH51srMdiwc947-juptRyKDdjgBhmUahzTaS2UBHuUJQLCyx2zmC6-809J7m4k8Il_ROAz6OUzP2aZdAX4kMmaZvtCaa-TmiMhxZyT4p-tc_gzm1ZnMsP_T4LlAnwiIb51E5NPe-gzKY-Vb5evVwiBZEJcaElpE3uyssb0XgOdUpFJFRHbstPOw7pVqPAoc4kppJrSMyMneok0TvBb3vtmT1ur_QRHv_u_u78kTFhwWKwuOyeFyvvIfAPIt84_B1_8AMRBOgA priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3ra9RAEF_aK_j44LNqtMoqgh9srnfJZh8fT2k5xBYFC_XTstlsvLN3yXHPnv7zziS50FgpCn4IhGQnm8zOK8zMbwl5HSWIKhI4P2GC-0wZ5xumuC8cD4OOM0YKbBQ-PuH9U_bhLDrbIp83vTDfCxhHYC7wo-zda1_uQx8VxhtO7PnBJElLnZf8YAZuSzAfS9PB6XSlv9omOxxzTi2yc3ryqfe1bIwMQCoU2zTP_JGw4aAKHP_aWm8PsFjyaiR6taCyzqreJjcX2cSsV2Y0uuS4ju6S6eaTy3qV8_ZiHrftj9_QIP8rT-6RO1WYS3ulXN4nWy57QG4cV4n8h-TnYY0yTvOUFlNXkBFgfqnJEjrEzpV8nCe4wVg-XdMJ5g2mCACLJGNsm7KD9RimQTBqiimIGR1mQEzdBV0OlznFFk18D3cxGYEI0WLfn11yenT45X3fr_aB8C0EG3M_iS1YCZaAW2HSwi9B0AliKSzEsqmRkeVJl_M4UqmzIghMrJgM0yCSoZE8TtNu-Ii0sjxzTwhVCFbDpGFWwMGDOJK2k4IRYk5ym3CPdDeLr20Fko57dYx08bMkuS65qoGruuCqXnnkbU0zKSFCrh39DmWqHonw3sWFfPpNV9ZCKyekgdgt7kJ8mHYCE7nESWeVcM5EPPbIG5RIjUYIF95UvRTwkQjnpXtcKaYQOMQje42RYDxs4_YrkOnGy_R7HzVeK7AdIRxddj3yciPyGumxLC9z-WKmEcmICQXe1iOPSxWonwWRfchDIT0iGsrRmKx5JxsOCoBzKVXAlfDI_kaNdGVZZ9dydr9Wtb9YiKf_NvwZuRUUqoRlD3ukNZ8u3HOIR-fxi8rC_AIOSYZ4 priority: 102 providerName: Unpaywall |
| Title | Evaluation of neuroprotective and immunomodulatory properties of mesenchymal stem cells in an ex vivo retinal explant model |
| URI | https://link.springer.com/article/10.1186/s12974-022-02418-w https://www.ncbi.nlm.nih.gov/pubmed/35236378 https://www.proquest.com/docview/2635479146 https://hal.sorbonne-universite.fr/hal-03598635 https://pubmed.ncbi.nlm.nih.gov/PMC8892697 https://jneuroinflammation.biomedcentral.com/track/pdf/10.1186/s12974-022-02418-w https://doaj.org/article/9e78a782b1584f02a5ede8ec97eea56b |
| UnpaywallVersion | publishedVersion |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: RBZ dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: KQ8 dateStart: 20040401 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: KQ8 dateStart: 20040101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: DOA dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: ABDBF dateStart: 20040101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: DIK dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: M~E dateStart: 20040101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: RPM dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Open Access Journals customDbUrl: eissn: 1742-2094 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: M48 dateStart: 20040701 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: AAJSJ dateStart: 20041201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: C6C dateStart: 20041201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBa9QNc9jN3nrQvaGOxh9ZbIsi4PY6ShpZS1lG2B7knIsrwGUjvLrQ378zvHsU1DSxl7MDG62IrPd3SOLZ3vEPIuTpFVhPkw5VKEXFsfWq5FKL2IWNtbqyQGCh-fiMM-PzqLz9ZIne6oeoCTW1_tMJ9Ufzz8ePV78QUU_nOp8Ep8moDNkjzEfelgcToqvFwnm3DCEOXHvFlViMC8szpw5tZ-22QLHJJIRJh17ZqdKun8m0l7_Rz3TN50SG_uq2wWV--Te7N8ZBeXdji8Zr8OHpIHleNJu0ukPCJrPn9Mto6rpfUn5M9-w_tNi4yWPJcViQNMiNTmKR1gLElxUaSY8qsYL-gIv-SPkZIVu1xgIJM7X1zAbZAemuKiwIQOcuhM_RWdD-YFxaBJHIe_Gg1BqLTMxPOU9A_2f_QOwyozQ-jA_E_DNHGgtzyFiZ4rB046a7NESQfeZWZV7ETaESKJdeadZMwmmqsoY7GKrBJJlnWiZ2QjL3L_glCN9DFcWe4kHIIlsXLtDKYF7pVwqQhIp5aDcRVtOWbPGJry9UUJsxSjATGaUozmMiAfmj6jJWnHna33ULxNSyTcLguK8S9T6a_RXioL3lTSAY8tazMb-9Qr77T03sYiCch7BIdBoMLwnK2iG-BPIsGW6QqtuUYqj4DsrLQEdXYr1W8BXiuDOex-NVhWsi2CgzjvBORNjT6D_XGjXO6L2cQgtxCXGuxfQJ4v0dhcq4Z2QOQKTldutlqTD85LynGlNBNaBmS3RrSpVfXOJ7vboP4fBPHyv8f1imyzUo1xT8IO2ZiOZ_41OIvTpEXW5Zlskc1u9-j7Efzu7Z-cfoPSnui1yg8wrXKOgJr-yWn3519t4m2L |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF7RVKJwQLwxFFgQEgdqEdvrfRwDahVC0gut1NtqvV6TSIkd5dmIP8-MY1tYRRUcfLF37I3n9cU78y0hH-IUWUVC56dMcJ8p43zDFPeF41HYdcZIgY3Co3Pev2SDq_iqagpb1tXu9ZJkGalLt5b88xIyk2A-Vp9DXgmkvz0ghzKOOeuQw15v8GNQR-AI0nhYN8j8VbKVhEqu_iYiH4yxIPIm2rxZNNmsnN4nR-t8bnZbM53-kZzOHpIHFaqkvb0ZPCJ3XP6Y3B1V6-ZPyK_ThtSbFhktSSwrhgaIdtTkKZ1go0gxK1Lcz6tY7OgcP9MvkG8VRWbYpWTHuxk8BrmfKX7xX9JJDsLUXdPNZFNQ7IjEebjr-RQ0Rsttdp6Sy7PTi699v9p2wbeQ21d-mlhwSpZCFGfSAgIPu2EihQXomBkZW54GnCexypwVYWgSxWSUhbGMjORJlgXRM9LJi9y9IFQhNwyThlkBBw-TWNpuBj7PnOQ25R4Jaj1oW3GS49YYU13-N5Fc73WnQXe61J3eeuRTIzPfM3LcOvoLqrcZiWza5Yli8VNXzqmVE9IAVEoCgGNZNzSxS510VgnnTMwTj3xE49Do8zA9a6rWBfiRyJ6le1wpppCnwyPHrZHgq7Z1-T2YV2sy_d5Q47mSShHQ3ybwyLva-jTKYxVc7or1UiNxEBMKkptHnu-tsbkXAOmIR0J6RLTstPWw9pV8Mi75xKVUIVfCIye1ResqkC1vfbMnjdX_gyJe_t_d35Kj_sVoqIffzr-_IvfC0nmx4uCYdFaLtXsNUHCVvKk8_zdYn1bh |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF7RVipwQLwKhgILQuJArSb2eh_HAI1CaCskqNTbar1ek0iJHeXZiD_PjF-qVVTBIRd7x15nXp-9M98S8j5KkFUkcH7CBPeZMs43THFfOB4GHWeMFNgofHbOBxdseBldXuviL6rd6yXJsqcBWZqy5fEsSUsXl_x4AVlKMB8r0SHHdKW_2SF7MlIcXr_2er3hj2EdjUNI6UHdLPNXyVZCKnj7m-i8M8LiyJvI82YBZbOKep_cXWUzs92YyeRaouo_JA8qhEl7pUk8Indc9pjsn1Vr6E_I75OG4JvmKS0ILSu2Boh81GQJHWPTSD7NE9zbK59v6Qw_2c-RexVFptixZEfbKdwGeaApfv1f0HEGwtRd0fV4nVPsjsR5uKvZBLRHiy13npKL_snPzwO_2oLBt5Dnl34SW3BQlkBEZ9ICGg86QSyFBRiZGhlZnnQ5jyOVOiuCwMSKyTANIhkayeM07YYHZDfLM_ecUIU8MUwaZgX8eBBH0nZS8H_mJLcJ90i31oO2FT85bpMx0cV7iuS61J0G3elCd3rjkY-NzKxk57h19CdUbzMSmbWLA_n8l64cVSsnpAHYFHcBmqWdwEQucdJZJZwzEY898gGNQ6P_w_SsqdoY4CGRSUv3uFJMIWeHRw5bI8Fvbev0OzCv1mQGvVONxwpaRUCC665H3tbWp1EeK-Iyl68WGkmEmFCQ6DzyrLTG5loAqkMeCukR0bLT1s3aZ7LxqOAWl1IFXAmPHNUWraugtrj1nz1qrP4fFPHi_67-hux__9LXp1_Pv70k94LCd7H44JDsLucr9wpQ4TJ-XTn-H2JpWys |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3ra9RAEF_aK_j44LNqtMoqgh9srnfJZh8fT2k5xBYFC_XTstlsvLN3yXHPnv7zziS50FgpCn4IhGQnm8zOK8zMbwl5HSWIKhI4P2GC-0wZ5xumuC8cD4OOM0YKbBQ-PuH9U_bhLDrbIp83vTDfCxhHYC7wo-zda1_uQx8VxhtO7PnBJElLnZf8YAZuSzAfS9PB6XSlv9omOxxzTi2yc3ryqfe1bIwMQCoU2zTP_JGw4aAKHP_aWm8PsFjyaiR6taCyzqreJjcX2cSsV2Y0uuS4ju6S6eaTy3qV8_ZiHrftj9_QIP8rT-6RO1WYS3ulXN4nWy57QG4cV4n8h-TnYY0yTvOUFlNXkBFgfqnJEjrEzpV8nCe4wVg-XdMJ5g2mCACLJGNsm7KD9RimQTBqiimIGR1mQEzdBV0OlznFFk18D3cxGYEI0WLfn11yenT45X3fr_aB8C0EG3M_iS1YCZaAW2HSwi9B0AliKSzEsqmRkeVJl_M4UqmzIghMrJgM0yCSoZE8TtNu-Ii0sjxzTwhVCFbDpGFWwMGDOJK2k4IRYk5ym3CPdDeLr20Fko57dYx08bMkuS65qoGruuCqXnnkbU0zKSFCrh39DmWqHonw3sWFfPpNV9ZCKyekgdgt7kJ8mHYCE7nESWeVcM5EPPbIG5RIjUYIF95UvRTwkQjnpXtcKaYQOMQje42RYDxs4_YrkOnGy_R7HzVeK7AdIRxddj3yciPyGumxLC9z-WKmEcmICQXe1iOPSxWonwWRfchDIT0iGsrRmKx5JxsOCoBzKVXAlfDI_kaNdGVZZ9dydr9Wtb9YiKf_NvwZuRUUqoRlD3ukNZ8u3HOIR-fxi8rC_AIOSYZ4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+neuroprotective+and+immunomodulatory+properties+of+mesenchymal+stem+cells+in+an+ex+vivo+retinal+explant+model&rft.jtitle=Journal+of+neuroinflammation&rft.au=Reboussin%2C+%C3%89lodie&rft.au=Buffault%2C+Juliette&rft.au=Brignole-Baudouin%2C+Fran%C3%A7oise&rft.au=R%C3%A9aux-Le+Goazigo%2C+Annabelle&rft.date=2022-03-02&rft.pub=BioMed+Central&rft.eissn=1742-2094&rft.volume=19&rft_id=info:doi/10.1186%2Fs12974-022-02418-w&rft_id=info%3Apmid%2F35236378&rft.externalDocID=PMC8892697 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon |